# Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)

> **NCT00170209** · PHASE3 · COMPLETED · sponsor: **McGill University** · enrollment: 844 (actual)

## Conditions studied

- Latent Tuberculosis Infection

## Interventions

- **DRUG:** Isoniazid
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT00170209
- **Lead sponsor:** McGill University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2014-11
- **Final completion:** 2015-05
- **Target enrollment:** 844 (ACTUAL)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170209, "Rifampin Versus Isoniazid for the Treatment of Latent Tuberculosis Infection in Children (P4v9)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00170209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*